September 12, 2016

Verseon Corporation (“Verseon” or the “Company”)

Additional Listing and Total Voting Rights

Verseon, a technology-based pharmaceutical company, announces that on 8 September 2016, Dr. Thomas Hecht, Non-Executive Chairman of the Company, has been issued restricted stock units ("RSUs") that relate to payment of his Director's fees in the form of restricted stock. Dr. Hecht's restricted stock grant totals 28,037 Common Shares and is calculated by reference to the closing price on 8 September 2016 of the Company's common shares in USD, being $2.14. The RSUs vest quarterly in equal proportions over a one year period starting from 29 April 2016 and accordingly 7,009 RSUs have now vested.

The Company announces that application has been made for 7,009 new Common Shares of par value $0.001 each (the "Common Shares") to be admitted to trading on AIM pursuant to regularly scheduled vesting of the restricted stock units (the "Issuance") to Dr. Hecht. Following Admission, Dr. Hecht will hold 24,300 Common Shares, representing 0.016% of the Company's issued share capital.

The 7,009 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on 16 September 2016 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 151,395,775 Common Shares. The Company does not hold any shares in treasury. Therefore the total number of Common Shares in the Company with voting rights will be 151,395,775. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information please contact:

Verseon Corporation +1 (510) 225 9000
Arthur Shmurun / Amy Thai
   
Cenkos (NOMAD and Broker) +44 (0) 20 7397 8900
Mark Connelly / Steve Cox  
   
Buchanan (PR Advisors) +44 (0) 20 7466 5000
Henry Harrison-Topham / Steph Watson
1Details of the person discharging managerial responsibilities / person closely associated
a)NameDr. Thomas Hecht
2Reason for the notification
a)Position/statusNon-Executive Chairman
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerseon Corporation
b)LEIN/A
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument

Identification code
Restricted stock grant of Common Shares of par value $0.001
b)Nature of the transactionIssuance of restricted stock units
c)Price(s) and volume(s)
Prices(s)Volume(s)
$2.1428,037
d)Aggregated information
— Aggregated volume
— Price

28,037
$2.14
e)Date of the transaction8 September 2016
f)Place of the transactionN/A

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen